TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Brief Summary: The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.


Options:
A: Arm Label: Exercise Training at Pulmonary Rehabilitation Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary Rehabilitation | Arm Label: Standard Treatment for IPF; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pulmonary Rehabilitation | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Exercise Training at Pulmonary Rehabilitation Program, Standard Treatment for IPF
B: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): 1
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Brief Summary: The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.


Options:
A: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Brief Summary: The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.


Options:
A: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): N/A
C: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Brief Summary: The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.


Options:
A: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
B: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-acetylcysteine (NAC) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine (NAC); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer
Brief Summary: The primary objective of this study is to compare median overall survival of the test arm (docetaxel and S-1) to the control arm (S-1 only) in subjects with advanced or recurrent gastric cancer.


Options:
A: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
B: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
C: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel + S-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1 | Intervention Type: DRUG; Name: docetaxel + S-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: S-1; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer
Brief Summary: The primary objective of this study is to compare median overall survival of the test arm (docetaxel and S-1) to the control arm (S-1 only) in subjects with advanced or recurrent gastric cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel + S-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1 | Intervention Type: DRUG; Name: docetaxel + S-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: S-1; Assigned to Arm(s): 2
C: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
D: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 3mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 10mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386 placebo, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: AMG 386 placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: AMG 386 10mg/kg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: AMG 386 3mg/kg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone-Based Genetic Counseling; An Equivalence Trial
Brief Summary: RATIONALE: Genetic counseling may work as well over the telephone as it does in-person. It is not yet known whether genetic counseling by telephone is more effective than standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.

PURPOSE: This randomized phase III trial is studying telephone-based genetic counseling to see how well it works compared to standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Education Counseling Session for PSA Screening | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Health Counseling Coaching | Intervention Type: BEHAVIORAL; Name: Education Counseling Session for PSA Screening; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: General Health Counseling Coaching; Assigned to Arm(s): Control Group
B: Arm Label: Telephone Genetic Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Genetic Counseling | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Telephone Genetic Counseling; Assigned to Arm(s): Telephone Genetic Counseling | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: You Decide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Reducing Your Risks in the Crash | Intervention Type: OTHER; Name: You Decide; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Reducing Your Risks in the Crash; Assigned to Arm(s): 2
D: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Decision Support & Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Decision Support & Navigation; Assigned to Arm(s): Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Standard

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy together with monoclonal antibodies before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving monoclonal antibodies after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without capecitabine and/or trastuzumab in treating breast cancer.

PURPOSE: This randomized phase III trial is studying epirubicin, cyclophosphamide, and docetaxel to compare how well they work with or without capecitabine and/or trastuzumab before surgery in treating women with stage I, stage II, or stage III breast cancer.


Options:
A: Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2
D: Arm Label: Arm A: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: Epirubicin, Drug: Cyclophosphamide | Arm Label: Arm B: ET-X; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Capecitabine, Drug: Epirubicin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm B: ET-X | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: EC-T

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI
Brief Summary: The incidence of stent restenosis in the setting of primary angioplasty is particularly high, reaching a rate of 27% In the last years the introduction of drug-eluting stents has drastically reduced the incidence of restenosis in patients not requiring urgent revascularization. Whether drug-eluting stenting might constitute the new optimal therapy for patients with an acute myocardial infarction is unknown. To be able to answer this question, we designed a randomized trial in which patients with an acute myocardial infarction eligible for treatment with primary angioplasty and abciximab were randomized to receive either a rapamicine-eluting stent or a conventional bare stent.


Options:
A: Arm Label: Bare metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous coronary intervention (PCI) | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: Percutaneous coronary intervention (PCI) | Intervention Type: DEVICE; Name: Percutaneous coronary intervention (PCI); Assigned to Arm(s): Bare metal stent | Intervention Type: DEVICE; Name: Percutaneous coronary intervention (PCI); Assigned to Arm(s): Drug eluting stent
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Intervention Type: DEVICE; Name: Drug Eluting Stent (DES); Assigned to Arm(s): A, B, C
C: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Primary angioplasty in acute myocardial infarction; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia
Brief Summary: The aim of this study is to assess longer term safety and effectiveness of Dysport®.


Options:
A: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF
B: Arm Label: Dysport®; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Dysport; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport

Answer: D